PD-1 Non-Small Cell Lung Cancer Clinical Trials 2024: FDA Approvals, Medication, Treatment Market, Therapies, MOA, ROA, Companies by DelveInsight

(Albany, USA) DelveInsight's 'PD-1 Non-Small Cell Lung Cancer Pipeline Insight 2024' report provides comprehensive global coverage of pipeline PD-1 non-small cell lung cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the PD-1 non-small cell lung cancer pipeline domain.

Request for Sample Report @ https://www.delveinsight.com/report-store/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Takeaways from the PD-1 Non-Small Cell Lung Cancer Pipeline Report
• DelveInsight's PD-1 non-small cell lung cancer pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for PD-1 non-small cell lung cancer treatment.
• Key PD-1 non-small cell lung cancer companies such as Summit Therapeutics, Arcus Biosciences, GlaxoSmithKline, Pfizer, AstraZeneca, Seagen, MacroGenics, Roche, Qilu Pharmaceutical, Shandong New Age Pharmaceutical, Symphogen, and others are evaluating new PD-1 non-small cell lung cancer drugs to improve the treatment landscape.
• Promising PD-1 non-small cell lung cancer pipeline therapies such as Ivonescimab, Zimberelimab, Dostarlimab, Sasanlimab, Rilvegostomig, SGN-PDL1V, Lorigerlimab, RO 7247669, QL1706, F520, Sym021, and others are under different phases of PD-1 non-small cell lung cancer clinical trials.
• In June 2024, Qilu Pharmaceutical presented trials in Progress poster presentation on QL1706 (iparomlimab/tuvonralimab), an innovative bifunctional antibody for immunotherapy, in two Phase III non-small cell lung carcinoma (NSCLC) clinical studies at the 2024 American Society of Clinical Oncology Annual Meeting (ASCO 2024).
• In May 2024, Summit Therapeutics announced that the first United States-based patient has been enrolled in the Phase III HARMONi study. HARMONi is a Phase III multiregional, randomized, double-blinded study. The study will evaluate the efficacy and safety of ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (TKI) such as osimertinib.
• In May 2024, Gilead Sciences and Arcus Biosciences announced updated results from an interim analysis of the ARC-7 study in patients with first-line, metastatic non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) 50% without epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutations. Progression-free survival curves showed early separation of both domvanalimab-containing arms from the zimberelimab arm, which was consistently maintained, and supports the potential therapeutic benefit of inhibiting the TIGIT pathway.
• In October 2022, Akeso Biopharma announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) granted Breakthrough Therapy Designation (BTD) for Ivonescimab (PD-1/VEGF bispecific antibody, AK112) combined with docetaxel for the treatment of locally advanced or metastatic Non-Small-Cell Lung Carcinoma (NSCLC) patients who failed to respond to prior PD-(L)1 inhibitor combined with platinum-based doublet chemotherapy.
• In October 2022, GSK announced positive headline results from PERLA, the phase II trial of Jemperli (dostarlimab) plus chemotherapy in patients with metastatic non-squamous non-small cell lung cancer. The safety and tolerability profile of dostarlimab in the PERLA phase II trial was consistent with previous clinical trials of similar regimens. The most common treatment-emergent adverse reactions were anemia, asthenia, nausea, constipation, cough, dyspnoea, vomiting, decreased appetite, and neutropenia.

Request a sample and discover the recent advances in PD-1 non-small cell lung cancer treatment drugs @ https://www.delveinsight.com/report-store/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

The PD-1 non-small cell lung cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage PD-1 non-small cell lung cancer drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the PD-1 non-small cell lung cancer clinical trial landscape.

PD-1 Non-Small Cell Lung Cancer Overview
Lung cancer is a cancer that begins in the lungs. Cancer develops when cells in the body begin to proliferate uncontrollably. Non-Small Cell Lung Cancer accounts for 80% to 85% of all lung cancers. Non-Small Cell Lung Cancer is classified into three subtypes: adenocarcinoma, squamous cell carcinoma, and big cell carcinoma. Because their treatment and prognosis are typically similar, these subtypes, which begin in distinct types of lung cells, are classed together as Non-Small Cell Lung Cancer.
Some persons with non-small cell lung cancer can be treated with drugs that target these checkpoints. Immunotherapies targeting programmed death ligand 1 (PD-L1) and its receptor (PD-1) have increased survival in a subset of advanced lung cancer patients. PD-L1 protein expression has emerged as a biomarker for predicting which individuals may respond better to immunotherapy. The history of using several immunohistochemistry platforms with different PD-L1 antibodies, scoring systems, and positivity cut-offs for immunotherapy clinical trials with distinct anti-PD-L1 and anti-PD-1 medicines complicates the understanding of PD-L1 as a biomarker.

Learn more about the emerging PD-1 non-small cell lung cancer pipeline therapies @ PD-1 Non-Small Cell Lung Cancer Clinical Trials - https://www.delveinsight.com/sample-request/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

PD-1 Non-Small Cell Lung Cancer Therapeutics Assessment
The PD-1 non-small cell lung cancer pipeline report proffers an integral view of the PD-1 non-small cell lung cancer emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

Scope of the PD-1 Non-Small Cell Lung Cancer Pipeline Report
• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Therapeutics Assessment By Route of Administration: Intravenous, Subcutaneous, Oral, Intramuscular
• Therapeutics Assessment By Molecule Type: Monoclonal antibody, Small molecule, Peptide
• Therapeutics Assessment By Mechanism of Action: Antibody-dependent cell cytotoxicity, Programmed cell death-1 receptor antagonists, Mitosis inhibitors, Tubulin polymerization inhibitors, Immunostimulants, Cell death stimulants, TIGIT protein inhibitors, Vascular endothelial growth factor receptor antagonists, T lymphocyte stimulants
• Key PD-1 Non-Small Cell Lung Cancer Companies: Summit Therapeutics, Arcus Biosciences, GlaxoSmithKline, Pfizer, AstraZeneca, Seagen, MacroGenics, Roche, Qilu Pharmaceutical, Shandong New age Pharmaceutical, Symphogen, and others
• Key PD-1 Non-Small Cell Lung Cancer Pipeline Therapies: Ivonescimab, Zimberelimab, Dostarlimab, Sasanlimab, Rilvegostomig, SGN-PDL1V, Lorigerlimab, RO 7247669, QL1706, F520, Sym021, and others

Dive deep into rich insights for new drugs for PD-1 non-small cell lung cancer treatment, visit @ PD-1 Non-Small Cell Lung Cancer Drugs - https://www.delveinsight.com/sample-request/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. PD-1 Non-Small Cell Lung Cancer Pipeline Report Introduction
2. PD-1 Non-Small Cell Lung Cancer Pipeline Report Executive Summary
3. PD-1 Non-Small Cell Lung Cancer Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. PD-1 Non-Small Cell Lung Cancer Clinical Trial Therapeutics
6. PD-1 Non-Small Cell Lung Cancer Pipeline: Late-Stage Products (Pre-registration)
7. PD-1 Non-Small Cell Lung Cancer Pipeline: Late-Stage Products (Phase III)
8. PD-1 Non-Small Cell Lung Cancer Pipeline: Mid-Stage Products (Phase II)
9. PD-1 Non-Small Cell Lung Cancer Pipeline: Early-Stage Products (Phase I)
10. PD-1 Non-Small Cell Lung Cancer Pipeline Therapeutics Assessment
11. Inactive Products in the PD-1 Non-Small Cell Lung Cancer Pipeline
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products in the PD-1 Non-Small Cell Lung Cancer Pipeline
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

Trending Reports:
• Clostridium Difficile Infections Cdi Market: https://www.delveinsight.com/report-store/clostridium-difficile-infections-clostridium-difficile-associated-disease-market
• Corneal Endothelial Dystrophy Market: https://www.delveinsight.com/report-store/corneal-endothelial-dystrophy-market
• Cutaneous Lupus Erythematosus Market: https://www.delveinsight.com/report-store/cutaneous-lupus-erythematosus-market
• Dermal Mycosis Market: https://www.delveinsight.com/report-store/dermal-mycosis-market
• Dlbcl Market: https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-market
• Epilepsy Market: https://www.delveinsight.com/report-store/epilepsy-market
• Epithelial Ovarian Cancer Market: https://www.delveinsight.com/report-store/ovarian-cancer-market
• Epithelioid Sarcoma Market: https://www.delveinsight.com/report-store/epithelioid-sarcoma-market
• Familial Chylomicronemia Syndrome Market: https://www.delveinsight.com/report-store/familial-chylomicronemia-syndrome-market
• Familial Primary Pulmonary Hypertension Market: https://www.delveinsight.com/report-store/familial-primary-pulmonary-hypertension-market
• Fuchs Dystrophy Market: https://www.delveinsight.com/report-store/fuchs-endothelial-corneal-dystrophy-fecd-market
• Graft Versus Host Disease Market: https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market
• Healthcare Competitive Intelligence: https://www.delveinsight.com/blog/competitive-intelligence-in-healthcare-sector
• Healthcare Due Diligence Services: https://www.delveinsight.com/consulting/due-diligence-services
• Healthcare Pipeline Analysis: https://www.delveinsight.com/consulting/pipeline-assessment-services
• Hemophilia With Inhibitor Market: https://www.delveinsight.com/report-store/hemophilia-a2030-market
• Hemorrhagic Cystitis Market: https://www.delveinsight.com/report-store/hemorrhagic-cystitis-market
• Hereditary Angioedema Market: https://www.delveinsight.com/report-store/hereditary-angioedema-market
• Hiatal Hernia Market: https://www.delveinsight.com/report-store/hiatal-hernia-market
• Hpv-induced Cancers Market: https://www.delveinsight.com/report-store/human-papillomavirus-16-positive-hpv16-cancers-market
• Hyperuricemia Market: https://www.delveinsight.com/report-store/hyperuricemia-market
• Hypoparathyroidism Market: https://www.delveinsight.com/report-store/hypoparathyroidism-market
• Lewy Body Dementia Market: https://www.delveinsight.com/report-store/lewy-body-dementia-market
• Menorrhalgia Market: https://www.delveinsight.com/report-store/menorrhalgia-market
• Metabolic Acidosis Market: https://www.delveinsight.com/blog/metabolic-acidosis-market
• Metrorrhagia Market: https://www.delveinsight.com/report-store/metrorrhagia-market
• Multiple Myeloma Market: https://www.delveinsight.com/report-store/multiple-myeloma-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/licensing-services

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.